Standard Biotools Stock Today
| LAB Stock | USD 1.71 0.09 5.56% |
Performance0 of 100
| Odds Of DistressOver 70
|
Standard Biotools is trading at 1.71 as of the 27th of November 2024, a 5.56 percent increase since the beginning of the trading day. The stock's open price was 1.62. Standard Biotools has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Standard Biotools are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of February 2024 and ending today, the 27th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of July 2003 | Category Healthcare | Classification Health Care |
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California. The company has 372.26 M outstanding shares of which 19.54 M shares are now shorted by investors with about 6.5 days to cover. More on Standard Biotools
Moving together with Standard Stock
Moving against Standard Stock
Standard Stock Highlights
| CEO President | Michael Egholm | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Measuring and Control Equipment (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Names | [Laboratory Corporation of America Holdings, Laboratory Corporation of America Holdings, Laboratory Corporation of America Holdings, Laboratory Corporation of America Holdings] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Measuring and Control Equipment, Health Care, Life Sciences Tools & Services, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsStandard Biotools can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Standard Biotools' financial leverage. It provides some insight into what part of Standard Biotools' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Standard Biotools (LAB) is traded on NASDAQ Exchange in USA. It is located in 2 Tower Place, South San Francisco, CA, United States, 94080 and employs 534 people. Standard Biotools is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 636.56 M. Standard Biotools runs under Life Sciences Tools & Services sector within Health Care industry. The entity has 372.26 M outstanding shares of which 19.54 M shares are now shorted by investors with about 6.5 days to cover.
Standard Biotools has about 81.31 M in cash with (43.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Standard Biotools Probability Of Bankruptcy
Ownership AllocationStandard Biotools shows a total of 372.26 Million outstanding shares. The majority of Standard Biotools outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Standard Biotools to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Standard Biotools. Please pay attention to any change in the institutional holdings of Standard Biotools as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Standard Ownership Details
Standard Biotools Historical Income Statement
Standard Stock Against Markets
Standard Biotools Corporate Management
| Jeffrey Black | Chief Officer | Profile | |
| Shane Bowen | Chief Officer | Profile | |
| Mark Spearman | Sr Communications | Profile | |
| Dr Dphil | CoFounder Board | Profile | |
| Peter DeNardo | Investor Relations | Profile | |
| Stephen Linthwaite | Advisor | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Standard Biotools. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Standard Biotools. If investors know Standard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Standard Biotools listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share 0.558 | Quarterly Revenue Growth (0.14) | Return On Assets (0.15) | Return On Equity (0.37) |
The market value of Standard Biotools is measured differently than its book value, which is the value of Standard that is recorded on the company's balance sheet. Investors also form their own opinion of Standard Biotools' value that differs from its market value or its book value, called intrinsic value, which is Standard Biotools' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Standard Biotools' market value can be influenced by many factors that don't directly affect Standard Biotools' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Standard Biotools' value and its price as these two are different measures arrived at by different means. Investors typically determine if Standard Biotools is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Standard Biotools' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.